Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
monarchE adjuvant abemaciclib in high-risk early HR+/HER2- breast cancer
2023-509671-17-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 34
01
Overview
Phase 3, randomised, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Invasive Disease-Free Survival (IDFS). Planned start Jan 2024; status: authorised.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-509671-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509671-17-00.